Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Naunyn Schmiedebergs Arch Pharmacol ; 393(12): 2529-2542, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-32372350

RESUMEN

Stachydrine is a natural product with multiple protective biological activities, including those involved in preventing cancer, ischemia, and cardiovascular disease. However, its use has been limited by low bioavailability and unsatisfactory efficacy. To address this problem, a series of stachydrine derivatives (A1/A2/A3/A4/B1/B2/B3/B4) were designed and synthesized, and biological studies were carried out in vitro and in vivo. When compared with stachydrine, Compound B1 exhibited better neuroprotective effects in vitro, and significantly reduced infarction size in the model of the middle cerebral artery occlusion rat model. Therefore, Compound B1 was selected for further research on ischemic stroke. Graphical abstract.


Asunto(s)
Isquemia Encefálica/prevención & control , Accidente Cerebrovascular Isquémico/prevención & control , Fármacos Neuroprotectores/síntesis química , Fármacos Neuroprotectores/uso terapéutico , Prolina/análogos & derivados , Animales , Animales Recién Nacidos , Isquemia Encefálica/metabolismo , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Células Cultivadas , Diseño de Fármacos , Evaluación Preclínica de Medicamentos/métodos , Accidente Cerebrovascular Isquémico/metabolismo , Prolina/síntesis química , Prolina/uso terapéutico , Ratas , Ratas Sprague-Dawley
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA